141 related articles for article (PubMed ID: 29620599)
1. Small-Fiber Neuropathy in a Pediatric Patient Following Anti-Tumor Necrosis Factor-α Therapy for Ulcerative Colitis.
Breton J; Ellazam B; Haddad E; Deslandres C
J Pediatr Gastroenterol Nutr; 2018 Jun; 66(6):e159-e161. PubMed ID: 29620599
[No Abstract] [Full Text] [Related]
2. Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis.
Baki E; Zwickel P; Zawierucha A; Ehehalt R; Gotthardt D; Stremmel W; Gauss A
World J Gastroenterol; 2015 Mar; 21(11):3282-90. PubMed ID: 25805935
[TBL] [Abstract][Full Text] [Related]
3. Peripheral Neuropathy Associated With Anti-Tumor Necrosis Factor Therapy: A Case Report and Review of the Literature.
Ertugrul Mut S; Tinazli M; Eker A; Akar S
J Clin Rheumatol; 2019 Oct; 25(7):e116-e118. PubMed ID: 29683835
[No Abstract] [Full Text] [Related]
4. Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease.
Holmstrøm RB; Mogensen DV; Brynskov J; Ainsworth MA; Nersting J; Schmiegelow K; Steenholdt C
Dig Dis Sci; 2018 Jun; 63(6):1583-1591. PubMed ID: 29564674
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Infliximab and Adalimumab in Biologic-Naive Patients With Ulcerative Colitis: A Nationwide Danish Cohort Study.
Singh S; Andersen NN; Andersson M; Loftus EV; Jess T
Clin Gastroenterol Hepatol; 2017 Aug; 15(8):1218-1225.e7. PubMed ID: 27913244
[TBL] [Abstract][Full Text] [Related]
6. Submandibular Sialoadenitis in an Infant Exposed to Adalimumab and Infliximab in Utero.
Vestergaard T; Brock B; Christensen LA; Julsgaard M
J Crohns Colitis; 2017 Oct; 11(10):1284-1285. PubMed ID: 28369262
[No Abstract] [Full Text] [Related]
7. Adalimumab-Receiving Ulcerative Colitis Patient Suffered Latent Tuberculosis Reactivation Despite Correct Chemoprophylaxis and was Successfully Treated while on Anti-Tumour Necrosis Factor Therapy.
Agudo B; Díaz G; González-Lama Y
J Crohns Colitis; 2016 Dec; 10(12):1453-1454. PubMed ID: 27215554
[No Abstract] [Full Text] [Related]
8. Prospective comparison of preference and efficacy of adalimumab and infliximab for treating ulcerative colitis naive to antitumor necrosis factor therapy.
Mizoshita T; Katano T; Tanida S; Hirano A; Miyaki T; Ozeki K; Suzuki Y; Sugimura N; Kataoka H; Joh T
Medicine (Baltimore); 2017 Aug; 96(32):e7800. PubMed ID: 28796080
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials.
Lopez A; Ford AC; Colombel JF; Reinisch W; Sandborn WJ; Peyrin-Biroulet L
Dig Liver Dis; 2015 May; 47(5):356-64. PubMed ID: 25661014
[TBL] [Abstract][Full Text] [Related]
10. Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response.
Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
J Clin Gastroenterol; 2015 Sep; 49(8):675-82. PubMed ID: 25389599
[TBL] [Abstract][Full Text] [Related]
11. Anti-TNF alpha medications and neuropathy.
Tsouni P; Bill O; Truffert A; Liaudat C; Ochsner F; Steck AJ; Kuntzer T
J Peripher Nerv Syst; 2015 Dec; 20(4):397-402. PubMed ID: 26309233
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcome of adalimumab therapy in patients with ulcerative colitis previously treated with infliximab: a Danish single-center cohort study.
Christensen KR; Steenholdt C; Brynskov J
Scand J Gastroenterol; 2015 Aug; 50(8):1018-24. PubMed ID: 25861832
[TBL] [Abstract][Full Text] [Related]
13. Multiple cutaneous leishmaniasis in patient with ulcerative colitis under treatment with adalimumab.
Sánchez-Bernal J; Aldea-Manrique B; Abadías-Granado I; Ara-Martín M
Med Clin (Barc); 2021 May; 156(9):475. PubMed ID: 32651069
[No Abstract] [Full Text] [Related]
14. Multifocal motor neuropathy following treatment with adalimumab for ulcerative colitis.
Fionda L; Vanoli F; Di Pasquale A; Leonardi L; Morino S; Antonini G
J Neurol; 2018 Jun; 265(6):1466-1468. PubMed ID: 29767352
[No Abstract] [Full Text] [Related]
15. Lack of efficacy of infliximab in the treatment of primary sclerosing cholangitis in inflammatory bowel diseases in childhood.
Cardile S; Candusso M; Papadatou B; Bracci F; Knafelz D; Torre G
Eur J Gastroenterol Hepatol; 2017 Jun; 29(6):736. PubMed ID: 28441268
[No Abstract] [Full Text] [Related]
16. Comparative Effectiveness of Infliximab and Adalimumab in Crohn's Disease and Ulcerative Colitis.
Ananthakrishnan AN; Cagan A; Cai T; Gainer VS; Shaw SY; Savova G; Churchill S; Karlson EW; Kohane I; Liao KP; Murphy SN
Inflamm Bowel Dis; 2016 Apr; 22(4):880-5. PubMed ID: 26933751
[TBL] [Abstract][Full Text] [Related]
17. Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents.
Eickstaedt JB; Killpack L; Tung J; Davis D; Hand JL; Tollefson MM
Pediatr Dermatol; 2017 May; 34(3):253-260. PubMed ID: 28211161
[TBL] [Abstract][Full Text] [Related]
18. Anti-TNFα Treatment in Children and Adolescents With Combined Inflammatory Bowel Disease and Autoimmune Liver Disease.
Nedelkopoulou N; Vadamalayan B; Vergani D; Mieli-Vergani G
J Pediatr Gastroenterol Nutr; 2018 Jan; 66(1):100-105. PubMed ID: 28953529
[TBL] [Abstract][Full Text] [Related]
19. Tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis: a retrospective observational study.
Yamamoto T; Shimoyama T; Umegae S; Matsumoto K
Aliment Pharmacol Ther; 2016 Mar; 43(6):705-16. PubMed ID: 26762838
[TBL] [Abstract][Full Text] [Related]
20. Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation.
Bortlik M; Duricova D; Machkova N; Hruba V; Lukas M; Mitrova K; Romanko I; Bina V; Malickova K; Kolar M; Lukas M
Scand J Gastroenterol; 2016; 51(2):196-202. PubMed ID: 26329773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
